Prothena Corporation plc's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses In Ongoing Phase 1 Study In Patients With Immunoglobulin Light Chain (AL) Amyloidosis
4/23/2014 2:51:48 PM
DUBLIN, Ireland, April 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract was published by the XIV International Symposium on Amyloidosis (ISA) and described interim data from an ongoing Phase 1 study of NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction, as of the abstract submission date. Updated data will be presented for the first time at ISA in Indianapolis, Indiana.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by